ArticleTranslational lung cancer research2026
Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have reshaped the management of advanced non-small cell lung cancer (NSCLC), yet only a subset of patients derive durable benefit and reliable predictive biomarkers remain limited. AT-rich interaction domain 1A ( Case Description: A 52-year-old Caucasian male was diagnosed with stage IIB lung adenocarcinoma with 30% programmed death-ligand 1 (PD-L1) expression and no common oncogenic driver mutations. He received neoadjuvant cisplatin-pemetrexed followed by left upper lobectomy and adjuvant chemotherapy. Two years later, surveillance imaging revealed mediastinal nodal recurrence. Next-generation sequencing (NGS) performed on the diagnostic and recurrent tumor samples identified a pathogenic Conclusions: This case supports a potential association between
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.